

Michela Rondoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8076777/publications.pdf>

Version: 2024-02-01

85
papers

1,539
citations

331259

21
h-index

315357

38
g-index

86
all docs

86
docs citations

86
times ranked

1875
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells. <i>Cell Biology and Toxicology</i> , 2023, 39, 795-811.	2.4	6
2	Rearrangements of ATP5L&KMT2A in acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 192, e139-e144.	1.2	3
3	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. <i>British Journal of Haematology</i> , 2021, 193, 845-848.	1.2	6
4	Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a. <i>Biomedicines</i> , 2021, 9, 388.	1.4	6
5	Adrenomedullin Expression Characterizes Leukemia Stem Cells and Associates With an Inflammatory Signature in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 684396.	1.3	6
6	MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S356-S357.	0.2	0
7	Poster: MPN-180: A Novel Mechanism of Action of Midostaurin in Systemic Mastocytosis: Beyond KIT Inhibition. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S233.	0.2	0
8	CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. <i>Blood</i> , 2021, 138, 1262-1262.	0.6	1
9	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.	2.8	28
10	MDS-227: Digital PCR for Sensitive Detection and Accurate Quantification of KIT D816V Allele Burden in Patients with Suspected Systemic Mastocytosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S320.	0.2	0
11	MPN-204: Midostaurin Synergizes with Nilotinib and Dasatinib Restoring SETD2 Expression and Activity in Advanced Systemic Mastocytosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S334.	0.2	0
12	CD22 Expression in B-Cell Acute Lymphoblastic Leukemia: Biological Significance and Implications for Inotuzumab Therapy in Adults. <i>Cancers</i> , 2020, 12, 303.	1.7	42
13	New monoclonal antibodies and tyrosine kinase inhibitors in B-cell acute lymphoblastic leukemia. <i>Minerva Medica</i> , 2020, 111, 478-490.	0.3	4
14	Real&world experience with decitabine as a first&line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy. <i>Hematological Oncology</i> , 2019, 37, 447-455.	0.8	25
15	Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients. <i>Blood</i> , 2019, 134, 1363-1363.	0.6	2
16	In Systemic Masocytosis, Midostaurin Targets Both Kit and Aurora Kinase a Reverting H3K36Me3 Deficiency and Synergizes with Second-Generation Tyrosine Kinase Inhibitors. <i>Blood</i> , 2019, 134, 4204-4204.	0.6	0
17	SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis. <i>Leukemia</i> , 2018, 32, 139-148.	3.3	28
18	The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. <i>Future Oncology</i> , 2018, 14, 2713-2723.	1.1	9

#	ARTICLE	IF	CITATIONS
19	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	0.6	3
20	MDM2 and Aurora Kinase a Contribute to SETD2 Loss of Function in Advanced Systemic Mastocytosis: Implications for Pathogenesis and Treatment. <i>Blood</i> , 2018, 132, 1779-1779.	0.6	1
21	Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients. <i>American Journal of Hematology</i> , 2016, 91, 692-699.	2.0	54
22	Serendipitous detection of Hemoglobin G-Ferrara variant with Sysmex DIFF channel. <i>Clinical Biochemistry</i> , 2016, 49, 192-193.	0.8	5
23	The Genomic and Transcriptomic Landscape of Systemic Mastocytosis. <i>Blood</i> , 2016, 128, 3136-3136.	0.6	1
24	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	2.0	93
25	A rare case of Hemoglobin Leiden interfering with the DIFF channel of Sysmex XE-2100. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2015, 75, 436-437.	0.6	9
26	Genome-Wide Molecular Portrait of Aggressive Systemic Mastocytosis and Mast Cell Leukemia Depicted By Whole Exome Sequencing and Copy Number Variation Analysis. <i>Blood</i> , 2015, 126, 4085-4085.	0.6	2
27	Abstract 3957: Integrated molecular characterization of mast cell leukemia reveals recurrent inactivation of the SETD2 tumor suppressor gene. , 2015, , .		0
28	Inactivation of the SETD2 Tumor Suppressor Gene in Mast Cell Leukemia. <i>Blood</i> , 2014, 124, 1881-1881.	0.6	2
29	PKC412 (midostaurin) is safe and highly effective in systemic mastocytosis: Follow up of a single-center Italian compassionate use.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7113-7113.	0.8	0
30	Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis. <i>Blood</i> , 2014, 124, 1856-1856.	0.6	0
31	A Survey on Clinical and Biological Characteristic and Therapy Management of an Italian Series of 455 Adult Patients with Systemic Mastocytosis on Behalf of Italian Registry of Mastocytosis. <i>Blood</i> , 2014, 124, 3188-3188.	0.6	0
32	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. <i>Blood</i> , 2013, 122, 2659-2659.	0.6	0
33	Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 84-85.	1.0	0
34	Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib. <i>Leukemia Research</i> , 2010, 34, e215-e216.	0.4	0
35	Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q deletion. <i>British Journal of Haematology</i> , 2010, 148, 483-484.	1.2	6
36	A der(1)t(1;21)(p36.3;q22) in a Patient with Acute Myelogenous Leukemia M2. <i>Acta Haematologica</i> , 2010, 124, 44-45.	0.7	0

#	ARTICLE	IF	CITATIONS
37	Complete molecular response in CML after p210 BCR-ABL-derived peptide vaccination. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 600-603.	12.5	26
38	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. <i>Blood</i> , 2010, 116, 3413-3413.	0.6	2
39	The New Italian Mastocytosis Registry.. <i>Blood</i> , 2010, 116, 3805-3805.	0.6	2
40	Abstract 656: High-resolution molecular allelokaryotyping identifies novel genomic alterations in acute promyelocytic leukemia (APL)., 2010, , .		0
41	RASGRP1/APTX Ratio Is a Strong Biomarker of Clinical Response and Survival In AML Patients Treated with Tipifarnib: A Phase III Preliminary Results. <i>Blood</i> , 2010, 116, 4359-4359.	0.6	0
42	Extreme Variability of FIP1L1-PDGFRalpha Transcripts In CEL: Analysis of 32 Patients Enrolled In HES0203 Italian Clinical Trial and Correlation with Clinical and Molecular Response After 5 Years Follow-up. <i>Blood</i> , 2010, 116, 1986-1986.	0.6	0
43	Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow up of 30 to 92 Months.. <i>Blood</i> , 2009, 114, 3894-3894.	0.6	1
44	BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.. <i>Blood</i> , 2009, 114, 648-648.	0.6	6
45	Four Drugs Combination (Fludarabine, Cytarabine, Idarubicin, Etoposide) as Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 65 Ys: Response and Follow-up of 84 Patients.. <i>Blood</i> , 2009, 114, 4147-4147.	0.6	0
46	Genome-Wide Analysis by High-Resolution SNP Array Identifies Novel Genomic Alterations in Acute Promyelocytic Leukemia (APL).. <i>Blood</i> , 2009, 114, 167-167.	0.6	1
47	Mast cell leukemia: a report of ten cases. <i>Annals of Hematology</i> , 2008, 87, 505-508.	0.8	41
48	PDGFRalpha/FIP1L1-positive chronic eosinophilic leukemia presenting with retro-orbital localization: efficacy of imatinib treatment. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 713-716.	1.1	4
49	Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>International Journal of Hematology</i> , 2008, 88, 483-488.	0.7	44
50	Long-term molecular complete remission with IFN- γ in Ph+ adult acute lymphoid leukemia patients. <i>Leukemia</i> , 2008, 22, 1617-1618.	3.3	8
51	Long-Term Mutation Follow-up of Philadelphia-Chromosome Positive Leukemia Patients Treated with Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure Shows That Newly Acquired Bcr-Abl Kinase Domain Mutations Leading to Relapse Are Mainly Detected during the First Year.. <i>Blood</i> , 2008, 112, 2118-2118.	0.6	1
52	Two Novel WT-1 Derived Peptides Induce CD4+ peptide-specific T Cell Proliferation in Patients with Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2008, 112, 5432-5432.	0.6	0
53	Induction Intensified Regimens Including Fludarabine or Mylotarg for Acute Myeloid Leukemia Patients: Comparison by Response and Follow-up.. <i>Blood</i> , 2008, 112, 941-941.	0.6	0
54	Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study. <i>Blood</i> , 2008, 112, 5223-5223.	0.6	0

#	ARTICLE	IF	CITATIONS
55	Imatinib mesylate in the treatment of hematologic malignancies. Expert Opinion on Biological Therapy, 2007, 7, 1597-1611.	1.4	23
56	Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica, 2007, 92, 401-404.	1.7	172
57	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR α -positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 2007, 92, 1173-1179.	1.7	198
58	Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFR α -positive chronic eosinophilic leukemia. Blood, 2007, 109, 4635-4640.	0.6	195
59	Hypereosinophilic Syndrome and Molecularly Targeted Therapy. Seminars in Hematology, 2007, 44, S4-S16.	1.8	17
60	Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL. Lancet Oncology, The, 2007, 8, 273-274.	5.1	39
61	Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study.. Haematologica, 2007, 92, 1721-1722.	1.7	15
62	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia, 2007, 21, 1442-1450.	3.3	22
63	Philadelphia Chromosome-Positive Leukemia Patients Who Harbor Imatinib-Resistant Mutations Have a Higher Likelihood of Developing Additional Mutations Associated with Resistance to Novel Tyrosine Kinase Inhibitors.. Blood, 2007, 110, 322-322.	0.6	7
64	Response to Dasatinib in Patients with Aggressive Systemic Mastocytosis with D816V Kit Mutation.. Blood, 2007, 110, 3562-3562.	0.6	5
65	Systematic Evaluation of Hypereosinophilic Syndrome-Related Organ Damage According to FIP1L1-PDGFR α Status and Response to the Therapy: Analysis from Prospective Clinical Trial with Imatinib Mesylate.. Blood, 2007, 110, 3557-3557.	0.6	21
66	Poor outcome of adult acute lymphoblastic leukemia patients carrying the (1;19)(q23;p13) translocation. Leukemia and Lymphoma, 2006, 47, 469-472.	0.6	24
67	Advances and potential treatment for Philadelphia chromosome-positive adult acute lymphoid leukaemia. Expert Opinion on Biological Therapy, 2006, 6, 1011-1022.	1.4	12
68	Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome-Positive Leukemia. Journal of Clinical Oncology, 2006, 24, e51-e52.	0.8	61
69	Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts).. Blood, 2006, 108, 836-836.	0.6	17
70	NPM Mutations and Not FLT3 Mutations Are a Potential Marker for Monitoring Minimal Residual Disease in Acute Myeloid Leukemia.. Blood, 2006, 108, 2016-2016.	0.6	0
71	Prevalence and Prognostic Significance of FLT3 Mutations in Acute Myeloid Leukemia: Association of ITDs with Poor Outcome in Patients with Normal Cytogenetics.. Blood, 2006, 108, 2017-2017.	0.6	0
72	Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?. Blood, 2005, 105, 904-905.	0.6	9

#	ARTICLE	IF	CITATIONS
73	Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. <i>British Journal of Haematology</i> , 2005, 131, 172-179.	1.2	43
74	Fludarabine Based Regimen (FLAI) Is an Effective Treatment for Induction of Multidrug Resistant Pgp-Positive Acute Myeloid Leukemia Patients.. <i>Blood</i> , 2005, 106, 1857-1857.	0.6	6
75	Imatinib Mesylate Can Induce Molecular Complete Remission in Idiopathic Hypereosinophilic Syndrome (HES). A Phase II Multicentric Italian Clinical Trial.. <i>Blood</i> , 2005, 106, 375-375.	0.6	3
76	Gemtuzumab Ozogamicin for Relapsed and Refractory Acute Myeloid Leukemia and Myeloid Sarcomas. <i>Leukemia and Lymphoma</i> , 2004, 45, 1791-1795.	0.6	67
77	Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia. <i>European Journal of Haematology</i> , 2004, 72, 302-303.	1.1	2
78	Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2004, 151, 85-86.	1.0	1
79	Prompt Resolution of Nasal Aspergillosis with Intra-Nasal Instillation of Liposomal Amphotericin-B (Ambisome®) and Granulocyte Transfusions. <i>Leukemia and Lymphoma</i> , 2004, 45, 637-638.	0.6	3
80	First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. <i>Leukemia Research</i> , 2004, 28, 987-990.	0.4	43
81	Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation. <i>Leukemia and Lymphoma</i> , 2004, 45, 731-733.	0.6	23
82	European Multicenter Experience on Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFR α Rearrangement treated with Imatinib.. <i>Blood</i> , 2004, 104, 1507-1507.	0.6	1
83	Efficacy and Toxicity of FLAI-G-CSF and Mylotarg for Induction/Consolidation of AML Patients, Not Treatable with Conventional Chemotherapy.. <i>Blood</i> , 2004, 104, 4514-4514.	0.6	0
84	The achievement of molecular complete remission during treatment with imatinib mesylate correlates with relapse-free survival in bcr/abl-positive acute lymphoid leukemia patients. <i>Haematologica</i> , 2004, 89, 1269-71.	1.7	8
85	Rapid Detection of Flt3 Mutations in Acute Myeloid Leukemia Patients by Denaturing HPLC. <i>Clinical Chemistry</i> , 2003, 49, 1642-1650.	1.5	24